专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08067388B2 Decoy-containing pharmaceutical compositions and method of using the same 有权
标题翻译：含诱饵的药物组合物及其使用方法
公开(公告)号：US08067388B2
公开(公告)日：2011-11-29
申请号：US12349824
申请日：2009-01-07
申请人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki
发明人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12Q1/68
CPC分类号： A61K9/127 , A61K31/711 , A61K38/08 , A61K38/1709 , A61K47/10 , A61K47/38 , A61K48/00 , A61K48/0008 , A61K48/005 , C12N15/113 , C12N15/86 , C12N2310/13 , C12N2710/10343 , C12N2740/13043
摘要： A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.
摘要翻译：提供药物组合物用于治疗和预防由NF-κB或ets控制的基因的表达引起的疾病。组合物包含至少一种诱饵和药学上可接受的载体。诱饵是NF-＆kgr; B诱饵，ets诱饵，或NF-＆kgr; B和ets的嵌合体诱饵。该疾病是脑动脉瘤，癌症，马凡氏综合征，主动脉分离，血管成形术后再狭窄，慢性关节风湿病，哮喘，特应性皮炎，肾炎，肾衰竭或斑块破裂。药学上可接受的载体可以是亲水性聚合物。

2. 发明申请

US20110045061A1 GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE 审中-公开
标题翻译：基因治疗糖尿病性疾病
公开(公告)号：US20110045061A1
公开(公告)日：2011-02-24
申请号：US12938128
申请日：2010-11-02
申请人： Ryuichi Morishita , Toshio Ogihara
发明人： Ryuichi Morishita , Toshio Ogihara
IPC分类号： A61K9/127 , A61K48/00 , A61P9/10
CPC分类号： A61K38/1833 , A61K9/127 , A61K9/1272 , A61K48/00 , A61K48/0016 , A61K48/0025 , A61K48/0075 , C07K14/4753 , C12N7/00 , C12N2760/18843
摘要： It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.
摘要翻译：可以通过将糖尿病性缺血性HGF（肝细胞生长因子）基因给予，从而刺激缺血部位的血管发生，并通过糖尿病降低并恢复缺血性疾病。

3. 发明申请

US20070259826A1 Chimeric (Double) Decoy 有权
标题翻译：嵌合（双）诱饵
公开(公告)号：US20070259826A1
公开(公告)日：2007-11-08
申请号：US11662777
申请日：2005-10-20
申请人： Ryuichi Morishita , Toshio Ogihara , Motokuni Aoki , Takashi Miyake
发明人： Ryuichi Morishita , Toshio Ogihara , Motokuni Aoki , Takashi Miyake
IPC分类号： A61K31/713 , A61K31/70 , A61K31/7105 , A61P17/06 , A61P35/04 , A61P41/00 , C07H21/02 , C07H21/04 , A61P9/10 , A61P37/08 , A61P29/00 , A61P17/00 , A61K31/711
CPC分类号： C12N15/113 , A61K48/00 , C12N2310/13 , C12N2310/3519
摘要： The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.
摘要翻译：本发明提供了一种用于血管再狭窄，缺血性疾病，过敏性疾病，炎性疾病，自身免疫性疾病或癌症转移，侵袭（癌症转移/侵袭）或恶病质的预防，改善或治疗药物，其基于对多种转录的抑制作用监管因素。本发明的嵌合体（双）诱饵在其单个分子中具有多个转录调节因子结合序列。因此，能够用单个分子抑制多个转录调节因子的活性。例如，人造血管的吻合部位的狭窄是由血管内膜的增厚引起的，这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。因此，通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子，可以抑制血管壁的增厚。

4. 发明申请

US20070142314A1 Decoy-containing pharmaceutical compositions and method of using the same 有权
标题翻译：含诱饵的药物组合物及其使用方法
公开(公告)号：US20070142314A1
公开(公告)日：2007-06-21
申请号：US11580748
申请日：2006-10-12
申请人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki
发明人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki
IPC分类号： A61K48/00
CPC分类号： A61K9/127 , A61K31/711 , A61K38/08 , A61K38/1709 , A61K47/10 , A61K47/38 , A61K48/00 , A61K48/0008 , A61K48/005 , C12N15/113 , C12N15/86 , C12N2310/13 , C12N2710/10343 , C12N2740/13043
摘要： A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.
摘要翻译：提供药物组合物用于治疗和预防由NF-κB或ets控制的基因的表达引起的疾病。组合物包含至少一种诱饵和药学上可接受的载体。诱饵是NF-kappaB诱饵，ets诱饵，或NF-kappaB和ets的嵌合体诱饵。该疾病是脑动脉瘤，癌症，马凡氏综合征，主动脉分离，血管成形术后再狭窄，慢性关节风湿病，哮喘，特应性皮炎，肾炎，肾衰竭或斑块破裂。药学上可接受的载体可以是亲水性聚合物。

5. 发明申请

US20060263422A1 Pharmaceutical composition containing decoy and use of the same 审中-公开
标题翻译：含有诱饵的药物组合物及其用途
公开(公告)号：US20060263422A1
公开(公告)日：2006-11-23
申请号：US11442585
申请日：2006-05-26
申请人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki , Hirofumi Makino
发明人： Ryuichi Morishita , Motokuni Aoki , Toshio Ogihara , Tomio Kawasaki , Hirofumi Makino
IPC分类号： A61K48/00 , A61K9/127
CPC分类号： A61K9/127 , A61K31/711 , A61K38/08 , A61K38/1709 , A61K47/10 , A61K47/38 , A61K48/00 , A61K48/0008 , A61K48/005 , C12N15/113 , C12N15/86 , C12N2310/13 , C12N2710/10343 , C12N2740/13043
摘要： A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.
摘要翻译：提供了用于治疗和/或预防由NF-κB或ets控制的基因的表达引起的疾病，病症和/或病症的药物组合物。组合物包含至少一种诱饵和药学上可接受的载体。诱饵是NF-kappaB诱饵，ets诱饵，或NF-kappaB和ets的嵌合体诱饵。该疾病是脑动脉瘤，癌症，马凡氏综合征，主动脉分离，血管成形术后再狭窄，慢性关节风湿病，哮喘，特应性皮炎，肾炎，肾衰竭或斑块破裂。或者，该疾病是与嗜酸粒细胞异常（例如，哮喘，血管疾病，过敏性疾病，寄生虫疾病）相关的疾病。药学上可接受的载体可以是亲水性聚合物，脂质体等。

6. 发明授权

US06248722B1 Medicament comprising HGF gene 失效
标题翻译：包含HGF基因的药物
公开(公告)号：US06248722B1
公开(公告)日：2001-06-19
申请号：US09029497
申请日：1998-06-09
申请人： Ryuichi Morishita , Toshio Ogihara , Toshikazu Nakamura , Tetsuya Tomita , Takahiro Ochi
发明人： Ryuichi Morishita , Toshio Ogihara , Toshikazu Nakamura , Tetsuya Tomita , Takahiro Ochi
IPC分类号： A61K31711
CPC分类号： A61K9/1271 , A61K9/1272 , A61K38/1833 , A61K48/00
摘要： The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF.
摘要翻译：本发明涉及包含HGF基因的药物。本发明的药物可以局部施用于靶器官，从而可以选择性地显示效果，从而最小化HGF的副作用。

7. 发明授权

US08067384B2 Chimera (double) decoy 有权
标题翻译：嵌合（双）诱饵
公开(公告)号：US08067384B2
公开(公告)日：2011-11-29
申请号：US11662777
申请日：2005-10-20
申请人： Ryuichi Morishita , Toshio Ogihara , Motokuni Aoki , Takashi Miyake
发明人： Ryuichi Morishita , Toshio Ogihara , Motokuni Aoki , Takashi Miyake
IPC分类号： C12N15/11 , C12N15/113 , C12N15/115
CPC分类号： C12N15/113 , A61K48/00 , C12N2310/13 , C12N2310/3519
摘要： The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.
摘要翻译：本发明提供了一种用于血管再狭窄，缺血性疾病，过敏性疾病，炎性疾病，自身免疫性疾病或癌症转移，侵袭（癌症转移/侵袭）或恶病质的预防，改善或治疗药物，其基于对多种转录的抑制作用监管因素。本发明的嵌合体（双）诱饵在其单个分子中具有多个转录调节因子结合序列。因此，能够用单个分子抑制多个转录调节因子的活性。例如，人造血管的吻合部位的狭窄是由血管内膜的增厚引起的，这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。因此，通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子，可以抑制血管壁的增厚。

8. 发明申请

US20090087916A1 Assay method for identifying drug candidate 审中-公开
标题翻译：鉴定候选药物的方法
公开(公告)号：US20090087916A1
公开(公告)日：2009-04-02
申请号：US10594927
申请日：2005-03-30
申请人： Naoyuki Sato , Masayasu Okochi , Yoshiaki Taniyama , Toshio Ogihara , Ryuichi Morishita
发明人： Naoyuki Sato , Masayasu Okochi , Yoshiaki Taniyama , Toshio Ogihara , Ryuichi Morishita
IPC分类号： G01N33/68 , A61N7/00 , C07H19/24 , C07D311/30 , C07H15/20 , C07C49/248 , C07D279/20 , C07K1/107
CPC分类号： G01N33/6896 , G01N2333/4709 , G01N2500/00 , G01N2500/04 , G01N2800/2821 , G01N2800/2835
摘要： The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which includes measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent. Moreover, the present invention provides a dissolution promoter to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains the compound obtained by the identification method as an active ingredient.
摘要翻译：本发明提供鉴定能够从原纤维或骨料中除去肽，寡肽，多肽或蛋白质的候选药物的方法，该方法包括在受试化合物存在下测定可溶性肽，可溶性寡肽，可溶性多肽或在溶剂中处于平衡状态的可溶性蛋白质。此外，本发明提供了从原纤维或聚集体中除去肽，寡肽，多肽或蛋白质的溶解促进剂，其含有通过鉴定方法获得的化合物作为活性成分。

9. 发明申请

US20090004260A1 MEDICAMENT COMPRISING HGF GENE 审中-公开
标题翻译：包含HGF基因的药物
公开(公告)号：US20090004260A1
公开(公告)日：2009-01-01
申请号：US12203661
申请日：2008-09-03
申请人： Ryuichi MORISHITA , Toshio Ogihara , Toshikazu Nakamura , Tetsuya Tomita , Takahiro Ochi
发明人： Ryuichi MORISHITA , Toshio Ogihara , Toshikazu Nakamura , Tetsuya Tomita , Takahiro Ochi
IPC分类号： A61K9/127 , A61K31/7088 , A61P9/00
CPC分类号： A61K9/1271 , A61K9/1272 , A61K38/1833 , A61K48/00
摘要： The present invention relates to a method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering to the area affected by the insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby the HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells.
摘要翻译：本发明涉及一种用于治疗HGF有效的受试者的外周循环不足或周围血管狭窄的方法，包括对受周围循环不足或周围血管狭窄影响的区域施用治疗有效量的含有与HGF编码序列可操作地连接的组成型启动子，由此表达HGF，促进血管内皮细胞的生长而不是血管平滑肌细胞。

10. 发明授权

US06936594B1 Gene therapy for cerebrovascular disorders 有权
标题翻译：基因治疗脑血管障碍
公开(公告)号：US06936594B1
公开(公告)日：2005-08-30
申请号：US09856374
申请日：2000-09-18
申请人： Ryuichi Morishita , Toshio Ogihara
发明人： Ryuichi Morishita , Toshio Ogihara
IPC分类号： A61K38/18 , A61K38/19 , A61K48/00 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00 , A01N65/00 , A61K9/127 , C12N15/74
CPC分类号： A61K38/1833 , A61K38/1866 , A61K48/00
摘要： By introducing hepatocyte growth factor (HGF) gene and/or vascular endothelial growth factor (VEGF) gene into the subarachnoid space in humans, cerebrovascular disorders such as cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, and Alzheimer's dementia can be effectively treated or prevented.
摘要翻译：通过将肝细胞生长因子（HGF）基因和/或血管内皮生长因子（VEGF）基因引入人类的蛛网膜下腔内，脑血管障碍如脑血管阻塞，脑梗塞，脑血栓形成，脑栓塞，中风，脑出血，moyamoya病，脑血管性痴呆和阿尔茨海默氏痴呆可以有效地治疗或预防。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式